A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain

• Status: Terminated
• Trial end date: 2011-05-01

Summary

Our hypothesis is that this study design, in which bevacizumab is added to one of six single agent chemotherapies with proven activity in metastatic breast cancer, will result in regression or stabilization of this disease in a safe and tolerable manner.

• Phase: Phase 2

Details

• Lead Sponsor: Duke University
• Collaborator: Genentech, Inc.
• Treatments: Albumin-Bound Paclitaxel; Bevacizumab; Capecitabine; Docetaxel; Gemcitabine; Irinotecan; Paclitaxel; Vinblastine; Vinorelbine